2024 ASCO Annual Meeting

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

02:00 PM

Duration 3hrs Chicago USA

Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study

Thomas D, Daniele G, Kim J-E, Gadgeel S, Ahn E, Paz-Ares L, Prenen H, Chen D, Fang J, Wilson TR, Simmons B, Barlesi F

Oncology | Lung Cancer

Duration 3hrs Chicago USA

MyTACTIC: activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers

Schwartzberg LS, Spigel DR, Vanderwalde A, Zuniga R, Hong J, Szado T, Yoo B, Passler L, Wong W, Darbonne WC, Daniel D

Oncology | Lung Cancer

Duration 3hrs Chicago USA

Inequities in timely treatment initiation for patients with acute myeloid leukemia treated in a predominantly community setting in the United States

Ma E, Eisfeld A-K, Odenike O, Patel A, Wang R, Yellow-Duke A, Montez M, Xu Y, Miu K, Hantel A

Oncology - Hematology | Acute Myeloid Leukemia

06:30 PM

Duration 3hrs Chicago USA

Atezolizumab, cobimetinib, and vemurafenib in patients with BRAFV600 mutation-positive melanoma with central nervous system metastases: Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study

Dummer R, Levesque M, Bellini E, Chen M, Hu Y, Wong T, Stassen K, Duhard P, Yan Y, Tawbi H

Oncology | Skin Cancer

08:00 PM

Duration 180mins S100bc / Live Stream

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): updated analysis from a Phase I/II study

Phillips T, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trneny M, Bartlett NL, Zaucha J, Wrobel T, Offner F, Filezac de L'Etang A, Relf J, Carlile DJ, Byrne B, Mulvihill E, Lundberg L, Dickinson M

Oncology | Mantle Cell Lymphoma

Duration 180mins Chicago, USA

First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2 negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses

Juric D, Kalinsky K, Turner N, Jhaveri K, Schmid P, Loi S, Saura C, Im SA, Sunpaweravong P, Li H, Musolino A, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Devine J, Stout T, Loibl S

Oncology | Breast Cancer

01:00 PM

Duration 180mins S100bc | Live Stream

Efficacy and safety of entrectinib▼ in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions

Desai A, Robinson G, Wu Y, Wang H, Basu E, Bagchi A, Casanova M, van Tilburg C, Campbell-Hewson Q, Armstrong AE, Andre N, Devlin CE, Wulff J, Cardenas A, Meneses-Lorente G, Hutchinson KE, Lian Q, Ryklansky C, Fox E, Gajjar A

Oncology | Lung Cancer

02:00 PM

Duration 3hrs Chicago USA

Association of machine learning (ML) derived histological features with transcriptomics based molecular subtypes in advanced renal cell carcinoma (RCC)

Niha Beig, Shima Nofallah, David McDermott, Robert Motzer, Thomas Powles, Brian Rini, Hartmut Koeppen, Romain Banchereau, Miles Markey, Isaac Finberg2, Geetika Singh2, Lauren Brunner2, Robert Egger2, Chintan Parmer, Jake Conway, Stephanie Hennek, Dan Ruderman, Samuel Vilchez, Mahrukh Huseni, Jennifer Giltnane

Oncology | Genitourinary cancer

Duration 3hrs Chicago USA

INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)

Juric D, Kalinsky K, Im SA, Ciruelos E, Bianchini G, Barrios C, Jacot W, Schmid P, Loi S, Rugo H, Craine V, Huchinson K, Flechais A, Thanopoulou E, Harbeck N

Oncology | Breast Cancer

Duration 3hrs Chicago USA

INAVO122: A Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC)

Swain S, Barrios C, Basho R, Curigliano G, Harbeck N, Huang CS, Karmo M, Loi S, Tolaney S,Turner N, Collier A, Henschel V, Swat A, Warburton S, Amair-Pinedo F, Corts J

Oncology | Breast Cancer

Duration 3hrs Chicago USA

pionERA Breast Cancer is a Phase III study of first-line giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor, in patients with estrogen-receptor positive, HER2-negative locally advanced/metastatic breast cancer with resistance to prior adjuvant endocrine therapy

Kalinsky K, Jeselsohn R, Bellet M, Fasching P, Gomez-Abuin G, Jung KH, Lavalle S, Valverde VL, Lu YS, Schwab R, Turner N, Xu T, Zambelli A, Andre F

Oncology | Breast Cancer

Duration 3hrs Chicago USA

Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A Phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

Wander S, Stemmer S, Rugo H, Im S, Lau P, Paluch-Shimon S, Cahuzac C, Collier A, Shah M, Ngo H, Schwab R, Zhu J, Oliveria M

Oncology | Breast Cancer

03:00 PM

Duration 3hrs Chicago USA

Real-world treatment patterns, healthcare resource utilization and costs of care among newly diagnosed patients with HR+/HER2- metastatic breast cancer

Abbass I, Ng C, Dillon A, Cheng A, Chen L, Du Toit Y, Basho R

Oncology | Breast Cancer

Duration 3hrs Chicago USA

Economic Impact of Longer Treatment Duration in First-Line for HR+/HER2- Metastatic Breast Cancer: A Retrospective Analysis

Abbass I, Ng C, Dillon A, Cheng A, Du Toit Y, Basho R

Oncology | Breast Cancer

01:00 PM

Duration 180mins Arie Crown Theater | Live Stream

Nishio M, Wu Y-L, Barlesi F, Ahn JS, Lee DH, Lee J-S, Zhong W, Horinouch H, Hockmair M, Tanaka H, Glogowski M, Rittmeyer A, Filder M, Wrona A, Mamolo C, Cardona A, Ruf F, Smoljanovic V, Solomon BJ

Oncology | Lung Cancer

Duration 180mins Arie Crown Theatre

BEAT-SC: A randomized Phase III study of bevacizumab or placebo in combination with atezolizumab, chemotherapy and etoposide in patients with extensive-stage small cell lung cancer (ES-SCLC)

Yuichiro Ohe, Makoto Nishio , Baohui Han, Satoshi Watanabe, Xiubao Ren, Shuji Murakami, Nong Yang, Isamu Okamoto, Gaofeng Li, Nobuyuki Katakami, Xianling Liu, Naoyuki Nogami, Yuki Nakagawa, Morihiko Hayashi, Toshihiro Nanki, Chunyu Qian, Nobuyuki Yamamoto

Oncology | Lung Cancer

Duration 90mins Chicago, USA

Circulating KIM-1 biomarker analysis in IMmotion010, a randomized Phase 3 study of adjuvant atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

Laurence Albiges, Axel Bex, Cristina Suarez, Robert Uzzo, Xiaobin Tang, Zoe June Assaf, Sarita Dubey, Erik Goluboff, Corey Carter, Romain Banchereau, Mahrukh Huseni, Sumanta Pal, Brian Rini

Oncology | Genitourinary cancer

02:00 PM

Duration 3hrs Chicago USA

Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): results from a Phase I/II study

Bartlett NL, Dickinson M, Hutchings M, Carlo-Stella C, Wu S-J, Leppa S, Trneny M, Corradini P, Offner F, Mulvihill E, Bottos A, Tchaleu FB, Baumlin P, Relf J, Lundberg L, Bachy E

Hematology - Oncology | Non Hodgkin Lymphoma

Duration 3hrs Chicago USA

Real-world patient outcomes in biomarker-selected early non-small cell lung cancer patients

Fawzi Abu Rous, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, Shirish Gadgeel

Oncology | Lung Cancer

Duration 3hrs Chicago USA

Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the Phase III Pola-R-CHP vs R-CHOP (POLARIX) study

Lue JK, Morschhauser F, Tilly H, Lenz G, Jardin F, Herrera AF, Sharman JP, Flowers CR, Friedberg JW, Trněný M, Herbaux C, Yan M, Jiang Y, Hirata JH, Batlevi CL, Sugidono M, Sahin D, Leung W, Harris W, Salles G, Sehn LH

Hematology - Oncology | Aggressive non Hodgkin lymphoma

Duration 3hrs Chicago USA

Mosunetuzumab with polatuzumab vedotin: subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)

Assouline S, Budde LE, Chavez JC, Diefenbach C, Dorritie K, Ghosh N, Olszewski AJ, Lossos IS, Mehta A, Modi D, Naik S, Smith SD, Makadia S, Pham S, Wu H, Batlevi CL, To I, Wei MC, Kamdar M

Hematology - Oncology | Aggressive non Hodgkin lymphoma

06:30 PM

Duration 3hrs Chicago USA

Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)

Skoulidis F, Cuppens K, Sacher A, Velcheti V, Lee D-H, Lin MT, Fernando TM, Li S, Bradley D, Zarak Crnkovic M, Mathisen M

Oncology | Lung Cancer

Duration 3hrs Chicago USA

ALK testing patterns in early non-small cell lung cancer: A real-world evidence study

Ticeana Leal, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, Jason Porter

Oncology | Lung Cancer

Duration 3hrs Chicago USA

Budget Impact Model of LungFlag™, a Predictive Risk Model for Lung Cancer Screening

Michael K. Gould, Eran Choman, Nicolò Olghi, Milan Obradovic, Sarika Ogale, Carolina Heuser Sanmartin

Oncology | Lung Cancer

Duration 3hrs Chicago USA

IMpower010: Disease-Free Survival Final Analysis and Second Overall Survival Interim Analysis Results After ≥5 years of Follow-up of a Phase III Study of Adjuvant Atezolizumab vs Best Supportive Care in Resected Stage IB-IIIA Non-Small Cell Lung Cancer

Heather A. Wakelee, Nasser Altorki, Caicun Zhou, Tibor Csőszi, Ihor O. Vynnychenko, Oleksandr Goloborodko, Achim Rittmeyer, Martin Reck, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, Chenqi Fu, Marcus Ballinger, Yu Deng, Minu K. Srivastava, Elizabeth Bennett, Barbara J. Gitlitz, Enriqueta Felip

Oncology | Lung Cancer

Duration 3hrs Chicago USA

J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients with non-small cell lung cancer (NSCLC) in Japan

Yasutaka Watanabe, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Masafumi Yamaguchi, Kozo Yoshimori, Masahiro Seike, Hironori Yoshida, Kazumi Nishino, Asako Miwa, Misa Tanaka, Akihiko Gemma

Oncology | Lung Cancer

Duration 3hrs Chicago USA

J-TAIL-2: A prospective, observational study of atezolizumab (atezo) combined with carboplatin and etoposide (CE) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in Japan

Ryota Saito, Masato Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi,Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Takashi Kijima, Kenichi Chikamori, Hisashi Tanaka, Kazunori Tobino, Tatsuro Fukuhara, Hirotaka Kuroki, Misa Tanaka, Akihiko Gemma

Oncology | Lung Cancer

01:00 PM

Duration 90mins S406 | On Demand

Atezolizumab in patients with tumor mutational burden-high (TMB) tumors from the TAPISTRY trial

Dziadziuszko R, Barlesi F, Kim J-E, Gadgeel S, Krzakowski M, Jeong J-H, Daniele G, Chen, D, Hu Y, Wilson T, Simmons B, Thomas D

Oncology | Lung Cancer

I am a healthcare professional

Notice

Cookies

External site

2024 ASCO Annual Meeting